天然产物 天然产物苯丙素类 Phenylpropanoids
Wedelolactone (Synonyms: 蟛蜞菊内酯) 纯度: 99.70%
Wedelolactone,是一种来自 Ecliptae herba 的天然产物,通过直接抑制 IKK 复合物来抑制 LPS 诱导的 caspase-11 表达。Wedelolactone 通过氧自由基清除机制抑制 5-脂氧合酶 (5-lipoxygenase, 5-Lox) (IC50~2.5 μM) 活性。Wedelolactone 通过下调 PKCε 诱导前列腺癌细胞中 caspase 依赖性细胞凋亡 (apoptosis) 而不抑制 Akt。具有抗癌,抗炎和抗氧化活性。
Wedelolactone Chemical Structure
CAS No. : 524-12-9
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
10 mM * 1 mL in DMSO | ¥553 | In-stock | |
5 mg | ¥800 | In-stock | |
10 mg | ¥1400 | In-stock | |
20 mg | ¥2300 | In-stock | |
50 mg | 询价 | ||
100 mg | 询价 |
* Please select Quantity before adding items.
Wedelolactone 相关产品
•相关化合物库:
- Natural Product Library Plus
- Bioactive Compound Library Plus
- Apoptosis Compound Library
- Immunology/Inflammation Compound Library
- Metabolism/Protease Compound Library
- Natural Product Library
- Anti-Cancer Compound Library
- Ferroptosis Compound Library
- Medicine Food Homology Compound Library
- Phenols Library
- Pyroptosis Compound Library
- Traditional Chinese Medicine Monomer Library
- FDA Approved & Pharmacopeial Drug Library
- Lipid Metabolism Compound Library
- Targeted Diversity Library
生物活性 |
Wedelolactone, a natural product from Ecliptae herba, suppresses LPS-induced caspase-11 expression by directly inhibiting the IKK Complex[1]. Wedelolactone inhibits 5-lipoxygenase (5-Lox) (IC50~2.5 μM) activity by an oxygen radical scavenging mechanism. Wedelolactone induces caspase-dependent apoptosis in prostate cancer cells via downregulation of PKCε without inhibiting Akt[2]. Anti-cancer, anti-inflammatory, and antioxidant activities[3]. |
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target[1][2][3] |
|
||||||||||||||||
分子量 |
314.25 |
||||||||||||||||
Formula |
C16H10O7 |
||||||||||||||||
CAS 号 |
524-12-9 |
||||||||||||||||
中文名称 |
蟛蜞菊内酯;蟛蜞内酯;蟛蜞菊内脂 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
|
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 125 mg/mL (397.77 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|